Design Therapeutics Q2 net loss $19.1M; FDA clinical hold on DT-216P2 US IND; cash $216.3M

Design Therapeutics, Inc.

2025-Q2 EPS reported -$0.65

Net loss of $19.1M for Q2 2025; R&D expense $15.7M, G&A $5.8M; cash and securities $216.3M as of June 30, 2025.
Early human PK data for DT-216P2 shows favorable translation from NHPs; improved AUC and sustained plasma levels vs DT-216P1.
FDA placed clinical hold on DT-216P2 US IND over starting dose; company plans to address with clinical/nonclinical data; RESTORE-FA trial continues outside US.
Phase 2 biomarker trial of DT-168 in Fuchs Endothelial Corneal Dystrophy patients has been initiated.
Preclinical DM1 program on track for development candidate selection in H2 2025; Huntington's disease preclinical characterization ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.